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OBJECTIVES We investigated changes in the clinical outcome of primary angioplasty and thrombolysis for
the treatment of acute myocardial infarction (AMI) from 1994 to 1998.
BACKGROUND Primary angioplasty for the treatment of AMI is a sophisticated technical procedure that
requires experienced personnel and optimized hospital logistics. Growing experience with
primary angioplasty in clinical routine and new adjunctive therapies may have improved the
outcome over the years.
METHODS The pooled data of two German AMI registries: the Maximal Individual Therapy in AMI
(MITRA) study and the Myocardial Infarction Registry (MIR) were analyzed.
RESULTS Of 10,118 lytic eligible patients with AMI, 1,385 (13.7%) were treated with primary
angioplasty, and 8,733 (86.3%) received intravenous thrombolysis. Patients characteristics
were quite balanced between the two treatment groups, but there was a higher proportion of
patients with a prehospital delay of .6 h in those treated with primary angioplasty. The
proportion of an in-hospital delay of more than 90 min significantly decreased in patients
treated with primary angioplasty over the years (p for trend 5 0.015, multivariate odds ratio
[OR] for each year of the observation period 5 0.84, 95% confidence interval [CI]: 0.73–
0.96) but did not change significantly in patients treated with thrombolysis. Hospital
mortality decreased significantly in the primary angioplasty group (p 5 0.003 for trend;
multivariate OR for each year 5 0.73, 95% CI: 0.58– 0.93). However, for patients treated
with thrombolysis, hospital mortality did not change significantly (p for trend 0.175,
multivariate OR for each year: 1.02, 95% CI: 0.94– 1.11).
CONCLUSIONS Compared with thrombolysis the clinical results of primary angioplasty for the treatment of
AMI improved from 1994 to 1998. This indicates a beneficial effect of the growing experience
and optimized hospital logistics of this technique over the years. (J Am Coll Cardiol 2000;
36:2064–71) © 2000 by the American College of Cardiology
Randomized controlled trials that compared primary percu-
taneous transluminal coronary angioplasty with thromboly-
sis have shown that primary angioplasty is more effective
than intravenous thrombolysis in reducing mortality and
morbidity in patients with acute myocardial infarction
(AMI) (1–6). However, concern persisted as to whether the
results of highly specialized centers could be applied to
clinical practice. Three myocardial infarction registries, the
Myocardial Infarction Triage Investigators (MITI) Registry
(7), the National Registry of Myocardial Infarction-2
(NRMI-2) (8) and a French registry (9), failed to show an
advantage of primary angioplasty compared with treatment
with thrombolysis in the “real world.” Only a more recent
registry (10) showed a more beneficial outcome with pri-
mary angioplasty compared with thrombolysis in a clinical
routine setting at 271 hospitals in Germany. The reasons for
this difference between the registries have not been studied
yet.
The results of primary angioplasty are related to the
experience of the performing physician (11–13). The intro-
duction of stents (14–20) and IIb/IIIa receptor antagonists
(21–23) in combination with primary angioplasty might
have improved the outcomes of primary angioplasty. How-
ever, treatment with thrombolysis has not changed very
From the *Herzzentrum Ludwigshafen, Kardiologie, Ludwigshafen, Germany;
†the Robert Koch Krankenhaus, Gehrden, Germany; ‡the Herzzentrum, Bad
Krozingen, Germany; §the Sta¨dtisches Klinikum, Nu¨rnberg, Germany; \the Klini-
kum Friedrichstadt, Dresden, Germany; ¶the Sta¨dtisches Klinikum, Dessau, Ger-
many. Supported, in part, by AstraZeneca, Bristol Myers-Squibb, Ministerium fu¨r
Gesundheit, Arbeit, Soziales des Landes Rheinland-Pfalz, Landesversicherungsan-
stalt Rheinland-Pfalz.
Manuscript received March 3, 2000; revised manuscript received May 22, 2000,
accepted July 13, 2000.
Journal of the American College of Cardiology Vol. 36, No. 7, 2000
© 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)00981-5
much over the last 15 years, with the exception of the
introduction of tissue plasminogen activator (24).
In order to investigate changes in clinical outcome of
primary angioplasty and thrombolysis from 1994 to 1998 in
patients with AMI, we analyzed the pooled data of two
German myocardial infarction registries: the Maximal In-
dividual Therapy in Acute Myocardial Infarction (MITRA)
study (25,26) and the Myocardial Infarction Registry (MIR)
(27).
METHODS
The MITRA study and the MIR were German prospective
multicenter observational studies of the current treatment of
AMI. The MITRA study recruited patients between June
1994 and January 1997. Fifty-four hospitals, mainly located
in the southwest of Germany, including university hospitals,
tertiary care centers and smaller hospitals, participated in
the study. The MIR study was a nationwide registry that
included patients from December 1996 to May 1998. A
total of 217 hospitals, mainly community hospitals, partic-
ipated. The protocols of both studies were almost identical.
No hospital participated in both studies. Therefore, we used
the pooled data from both studies for this analysis. All
patients presenting within the first 96 h of the onset of pain
were registered prospectively, as soon as the diagnosis of
AMI had been made.
Reperfusion therapy. The following protocols for intrave-
nous thrombolysis were suggested: intravenous application
of 1.5 million U of streptokinase over 1 h or tissue
plasminogen activator at a dose of 100 mg over 1.5 h
intravenously. Angioplasty was performed according to the
standard protocol of each center. The decision regarding the
type of treatment was left to the discretion of the treating
physician and not to the study protocol.
Definitions. Acute myocardial infarction was diagnosed in
the presence of the two following criteria: persistent angina
pectoris for $20 min and ST segment elevation of $1 mm
in at least 2 standard leads or $2 mm in at least 2
contiguous precordial leads or the presence of a left bundle
branch block. It was later confirmed by the elevation of
cardiac enzymes of more than twice the normal upper range.
Prehospital delay was defined as the time from the onset of
symptoms until hospital admission. In-hospital delay was
defined as the time from admission to the hospital until the
start of primary angioplasty (angiographic needle entry 5
door-to-needle entry time) or the start of the infusion of the
thrombolytic agent (door-to-needle time). A combined
clinical end point was defined by the occurrence of death or
reinfarction.
In this analysis only lytic eligible patients, that is, patients
without contraindications against thrombolysis, treated with
either primary angioplasty or intravenous thrombolysis and
a prehospital delay of no longer than 12 h were included.
Contraindications for thrombolysis were defined as stroke
within the last 3 months, surgery or trauma within the last
14 days or active bleeding.
Statistics. DATA COLLECTION. Data of the prehospital pe-
riod and the early intrahospital period (48 h) were collected
within the first two to three days at the intensive care unit.
Clinical events of the following hospital stay were reported
on a separate record form at hospital discharge. Every
participating center was committed by written consent to
include each patient with AMI during the study period. The
patients gave informed consent for processing of their
anonymous data. All data sheets were sent to the central
data processing center (Department of Cardiology, Herz-
zentrum Ludwigshafen) for uniform monitoring and regis-
tration.
DATA ANALYSIS. Absolute numbers, percentages and medi-
ans were computed to describe the patient population.
Categorical values were compared by chi-square analysis or
Fisher exact test as appropriate. Continuous variables were
compared by two-tailed Wilcoxon rank sum test. The
Cochran-Armitage trend test was used to analyze trends in
proportions. Multiple logistic regression analysis was used
to adjust for factors influencing hospital mortality, reinfarc-
tion and the combined end point during different years.
Multiple logistic regression analysis was also performed for
patients treated with primary angioplasty and for patients
treated with thrombolysis to look for changes of the results
of each therapy over the years. The following variables were
examined: age, gender, location of infarction, prevalence of
cardiogenic shock, previous myocardial infarction, resusci-
tation, heart failure at admission and the type of revascu-
larization or the year of the recruitment. The presence of
cardiogenic shock and resuscitation were not registered in
1994. Therefore, these parameters could not be included in
the regression analysis of this year. p values , 0.05 were
considered statistically significant. All p values are the
results of two-tailed tests. The tests were performed using
the SAS statistical package, version 6.12 (Cary, North
Carolina).
RESULTS
During 1994 and 1998 10,118 patients with AMI, a
prehospital delay #12 h and no contraindication for throm-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AMI 5 acute myocardial infarction
CI 5 confidence interval
MIR 5 Myocardial Infarction Registry
MITI 5 Myocardial Infarction Triage
Investigators Registry
MITRA 5 Maximal Individual Therapy in
Acute Myocardial Infarction
Registry
NRMI-2 registry 5 National Registry of Myocardial
Infarction-2
OR 5 odds ratio
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bolysis who were treated with either primary angioplasty or
thrombolysis were recruited by the MITRA and MIR
registries. Of these patients, 1,385 (13.7%) were treated
with primary angioplasty, and 8,733 (86.3%) received intra-
venous thrombolysis.
Patients characteristics and concomitant medication.
Patients characteristics and concomitant medication initi-
ated within the first 48 h after admission are shown in Table
1. Prehospital delays increased over the years in patients
treated with primary angioplasty but not in patients treated
with thrombolysis. This was caused by an increase in the
proportion of patients with a prehospital delay .6 h in the
primary angioplasty group (5.6% in 1994 to 12.1% in 1998).
There was a higher proportion of patients with prior
myocardial infarction and a lower rate of patients with heart
failure at admission for patients treated with primary angio-
plasty compared with those treated with thrombolysis.
Door-to-needle times for thrombolysis were always shorter
than the in-hospital delay until the start of primary angio-
plasty. However, the proportion of an in-hospital delay of
more than 90 min significantly decreased in patients treated
with primary angioplasty over the years (p for trend 5
0.015, multivariate analysis: odds ratio [OR] for each year:
OR 5 0.84, 95% confidence interval [CI]: 0.73 to 0.96). In
both treatment groups the use of beta-adrenergic blocking
agents and angiotensin-converting enzyme (ACE) inhibi-
tors increased over the years. The use of aspirin and
beta-blockers was not much different between the two
treatment groups. However, patients treated with primary
angioplasty were always more likely to receive ACE inhib-
itors.
Clinical events during 1994 to 1998. Hospital mortality
decreased significantly from 1994 to 1998 in patients treated
with primary angioplasty (p 5 0.003 for trend) (Table 2,
Fig. 1). This was confirmed by multiple logistic regression
analysis after adjustment for other confounding parameters,
showing an independent association of each following year
with a lower mortality (OR 5 0.73, 95% CI: 0.58 to 0.93).
The reinfarction rate (p for trend 0.001, multivariate anal-
ysis: OR for each year: 0.56, 95% CI: 0.39 to 0.81), and the
rate of the combined end point of death or reinfarction
decreased significantly from 1994 to 1998 (p for trend 5
0.001, multivariate analysis: OR for each year 5 0.70, 95%
CI: 0.56 to 0.86) (Table 2).
For patients treated with thrombolysis, neither hospital
mortality (p for trend 0.175, multivariate analysis: OR for
each year: 1.02, 95% CI: 0.94 to 1.11, Fig. 1) nor the
reinfarction rate (p for trend 0.937; multivariate analysis:
OR for each year: OR 5 1.09, 95% CI: 0.97 to 1.23) or the
rate of the combined end point of death or reinfarction (p
for trend 0.182; multivariate OR for each year: 1.05, 95%
CI: 0.97to 1.13, Table 2) changed significantly over the
years.
When we compared the results of primary angioplasty
with those of thrombolysis for each year, we found a
continuously increasing benefit associated with primary
angioplasty from 1994 to 1998. This benefit reached statis-
tical significance in 1997 and 1998 for hospital mortality,
Table 1. Patients Characteristics and Concomitant Medication Stratified by Year of Treatment in Patients Treated With Primary
Angioplasty Compared With Patients Treated With Thrombolysis
Year of Treatment
1994 1995 1996 1997 1998
pPTCA
n 5 36
(%)
Lysis
n 5 532
(%)
pPTCA
n 5 189
(%)
Lysis
n 5 1,139
(%)
pPTCA
n 5 182
(%)
Lysis
n 5 1,154
(%)
pPTCA
n 5 664
(%)
Lysis
n 5 4,599
(%)
pPTCA
n 5 314
(%)
Lysis
n 5 1,309
(%)
Age (years) 60 63 62 64 62 63 62 64‡ 63 64
Men 72.2 69.7 69.8 71.3 80.2 72.6† 74.1 72.2 74.9 69.6
Anterior wall MI 52.8 49.6 46 48.8 44.1 48.1 48 47.2 48.3 47.3
Heart rate (1/min) 78 80 78 79 78 78 78.5 77 78 77
Previous MI 36.1 16.9‡ 19.8 15.4 17 13.8 17.9 13.8‡ 13.1 14.1
Heart failure at ad. 0 4.9 3.2 5.5 1.1 4.9† 2.3 5.5§ 4.1 5.4
Resuscitation * * 7.9 7.4 4.4 7.5 6.2 7.1 7.6 7.9
Cardiogenic shock * * 6.2 4.2 2.8 3.2 4.7 4.4 6.7 3.7†
Ph delay (min) 120 120 130 120† 150 120‡ 165 120§ 150 125§
Ih delay (min) 84 30§ 65 30§ 90 30§ 70 30§ 67 30§
Concomitant
medication,
initiated during
the first 48 h after
admission:
Aspirin 94.4 94.2 95.2 97.7† 99.5 98.6 97.3 95.5 97.4 96.7
Beta-blockers 47.2 38.9 67.7 60.1† 66.9 66.2 69.7 65.7† 74.8 69.8
ACE inhibitors 36.1 12.8§ 66.1 55.8§ 68.7 62.2 62.1 57.5† 69.6 64.4‡
*Not evaluated in 1994; †p , 0.05; ‡p , 0.01; §p , 0.001.
ACE 5 angiotensin converting enzyme; ad. 5 admission; ih delay 5 in-hospital delay, that is “door to needle-entry”, or “door to needle”-time; Lysis 5 thrombolysis; MI
5 myocardial infarction; ph delay 5 prehospital delay; pPTCA 5 primary angioplasty.
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reinfarction and the combined end point (univariate analy-
sis: Table 2; multivariate analysis: Fig. 2 and 3).
DISCUSSION
Many studies showed a declining mortality from coronary
heart disease in the U.S. (28–31) and Western Europe (32)
over the last 20 years. This reduction in mortality is assumed
to be due to a declining incidence of myocardial infarction
in the population and an improved survival of patients with
myocardial infarction. The improved case fatality rates seem
to be mainly attributable to the increasing use of reperfusion
therapy (thrombolysis or primary angioplasty) and adjunc-
tive medical therapy such as antiplatelet therapy, beta-
blockers and ACE inhibitors. To the best of our knowledge,
there are no data in the literature on changes in mortality in
thrombolysis-eligible patients treated with either thrombol-
ysis or primary angioplasty.
Selection of patients and patterns of treatment. The
distribution of high-risk patients seemed to be balanced
between the two treatment groups. There was no major
difference in the age of the patients. Patients treated with
primary angioplasty were more likely to have a prior
myocardial infarction, and patients treated with thrombol-
ysis more often showed signs of heart failure at admission.
Important differences were seen in pre- and in-hospital
delays. Compared with thrombolysis primary angioplasty
was more often used in patients presenting with a prehos-
pital delay of more than 6 h. This preference for primary
angioplasty for patients with longer prehospital delays may
result from differences between the hospitals with angio-
plasty facilities and those hospitals without such facilities.
Hospitals with a catheterization laboratory are usually big-
ger than those without and are more likely to have cardiol-
ogists on call. Treatment by specialists may result in a better
adherence to current recommendations (33,34), which ad-
vise the use of reperfusion therapy for up to 12 h after the
onset of symptoms for patients with AMI (35). The
beneficial effect of thrombolysis compared with no reperfu-
sion therapy decreases with increasing prehospital delay
(36). This may not be true in the same amount for primary
angioplasty (37,38). This observation may also have con-
tributed to the more liberal use of primary angioplasty for
patients with longer prehospital delays.
Median in-hospital time to treatment was about 40 to
60 min longer for primary angioplasty than it was for
thrombolysis. However, these “door to needle-entry” times
for primary angioplasty were within 90 min, as recom-
mended by the American Cardiac Societies.
Although adjunctive therapy within the first 48 h after
admission with aspirin, beta-blockers and ACE inhibitors
increased in both treatment groups over the years, patients
treated with primary angioplasty were still more likely to be
treated with ACE inhibitors. This may be mainly attribut-
able to differences between hospitals as mentioned above.Ta
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Hospital events. Hospital mortality, reinfarction rate and
the combined end point of death or reinfarction decreased
significantly in patients treated with primary angioplasty
from 1994 to 1998, even after adjustment for confounding
parameters. Hospital mortality decreased from 13.9% in
1994 to 3.8% in 1998 (p for trend 5 0.001, multivariate
analysis: OR for each year: OR 5 0.73, 95% CI: 0.58 to
0.93). There were no significant changes in outcome for
patients treated with thrombolysis.
In the MITRA/MIR registries mortality for patients
treated with primary angioplasty in 1994 and 1995 was
higher (13.9% and 9.5%) compared with that of other
primary angioplasty studies (5.2% to 9.2%) (4,6–9,39), but
mortality decreased in the following years. Mortality in
patients treated with thrombolysis (11.3%) was constantly
higher than the mortality reported by these other studies
(5.4% to 7.6%). This difference in mortality between the
MTRA/MIR and the other studies may be caused by
different patient selection. In the MITRA/MIR studies
patients in cardiogenic shock were not excluded. Patients
were three years older, and anterior wall infarctions occurred
more often compared with the NRMI-2 registry (8).
Thrombolysis has not changed very much over the last 15
years with the exception of the introduction of tissue
plasminogen activator, which was demonstrated to be
slightly superior to streptokinase (about 1% absolute risk
reduction) (24). Therefore, the nearly constant mortality
rate in these patients was not surprising.
Primary angioplasty, however, is not such an easy-to-
perform therapy as thrombolysis. The results of primary
angioplasty strongly depend on the experience of the phy-
sician, a well-trained catheterization team and optimal
hospital logistics to keep in-hospital times as short as
possible. All those factors have proven to influence the
Figure 1. Hospital mortality in patients treated with primary angioplasty or thrombolysis from 1994 to 1998.
Figure 2. Multiple logistic regression analysis of hospital mortality comparing primary angioplasty with thrombolysis.
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outcome of primary angioplasty (12,13,40,41). Deficiencies
of these factors at low volume hospitals for primary angio-
plasty have led to strict recommendations for performing
primary angioplasty (35). Such differences between highly
specialized hospitals and low volume hospitals have also
been suggested to be the reason why registries (7–9)
comparing primary angioplasty with thrombolysis in the
“real world” failed to demonstrate a benefit of primary
angioplasty as did randomized controlled trials (1–6,39).
Our data demonstrate a clear improvement in clinical
outcome by treatment with primary angioplasty over the last
years. One reason might be the growing experience of the
treating physicians with primary angioplasty and improved
clinical logistics. This hypothesis is supported by the records
showing a decreasing proportion of patients with more than
90 min delay between admission to the hospital and the
beginning of primary angioplasty. Berger et al. (41) and
Cannon et al. (37) could show that shorter in-hospital
delays are associated with a better clinical outcome. Another
contributing factor could have been the recent introduction
of stents (14–20) and IIb/IIIa receptor antagonists (21–23)
in combination with primary angioplasty. However, the
most recent data of the Controlled Abciximab and Device
Investigation to Lower Late Angioplasty Complications
(CADILLAC) trial (42), presented at the American Heart
Association Scientific Meeting 1999 in Atlanta, Georgia,
showed only a minor benefit of either adjunctive stenting or
the use of abciximab in conjunction with primary angio-
plasty in AMI. The slightly higher use of beta-blockers and
ACE inhibitors for patients treated with primary angio-
plasty compared with those treated with thrombolysis could
have also contributed to the lower mortality. However, the
proportion of patients being treated with these concomitant
medications rose similarly in both treatment groups over the
years.
We concluded that between 1994 and 1998 primary
angioplasty for AMI was associated with a decreasing
hospital mortality and reinfarction rate, whereas those
events did not change in patients treated with thrombolysis.
The most probable explanation for the improving outcome
with primary angioplasty seems to be the growing experi-
ence of the physicians and the better hospital logistics.
Study limitations. This analysis of the MITRA and MIR
data suffers from the limitations faced by all registries. Since
MITRA and MIR are observational studies, it is not
possible to control totally for the selection of patients to be
treated with one of the two therapies. We did not collect
information about the rate of technical success (Thrombol-
ysis in AMI [TIMI] flow grade 3) of the angioplasty
procedures or the use of stents and IIb/IIIa receptor
inhibitors, so we were unable to control the results for these
important variables. Therefore, it is not possible to draw
definitive conclusions as to the mechanism responsible for
the changing differences in short-term outcome between
primary angioplasty and thrombolysis over the years. No
hospital participated in both registries. Therefore, selection
bias of the hospitals performing primary angioplasty could
be present in the two registries. However, there was no
apparent difference in the kind of angioplasty facilities in
both registries (mainly community hospitals, only a few
university hospitals). The trend of a decreasing mortality
associated with primary angioplasty over the years was
independently observed in the MITRA database and in the
MIR database. Although we could analyze data from 1,385
patients treated with primary angioplasty, this number is
much lower than the 8,733 patients who received intrave-
nous thrombolysis. Therefore, other AMI registries should
try to analyze their data accordingly in order to verify our
results.
APPENDIX
The people and institutions who participated in the
MITRA and MIR study are listed elsewhere (25,27).
Reprint requests and correspondence: Dr. Ralf Zahn, Herzzen-
trum Ludwigshafen, Department of Cardiology, Bremserstrabe
79, D - 67063 Ludwigshafen, Germany. E-mail: erzahn@aol.com.
Figure 3. Multiple logistic regression analysis of the combined end point of death or reinfarction comparing primary angioplasty with thrombolysis.
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